SPIKET and COBRA compounds as novel tubulin modulators with potent anticancer activity.
Agents that either promote or inhibit tubulin polymerization exhibit anticancer activity by disrupting normal mitotic spindle assembly and cell division as well as inducing apoptosis. Recently identified novel agents that target tubulin include synthetic spiroketal pyrans (SPIKET), targeting the spongistatin binding site of beta-tubulin, and COBRA compounds, targeting a unique binding cavity on alpha-tubulin. At nanomolar concentrations, the SPIKET compound SPIKET-P caused tubulin depolymerization in cell-free turbidity assays and exhibited potent cytotoxic activity against cancer cells as evidenced by destruction of microtubule organization, and prevention of mitotic spindle formation in human breast cancer cells. Molecular modeling studies predicted a high-affinity interaction of the first COBRA compounds, COBRA-0 and COBRA-1, with a unique hydrophobic binding site on alpha-tubulin located between the GTP/GDP binding site and the M-loop. Further studies showed that COBRA-1 inhibited GTP-induced tubulin polymerization in cell-free tubulin turbidity assays. Treatment of human breast cancer and brain tumor (glioblastoma) cells with COBRA-1 caused destruction of microtubule organization and apoptosis. COBRA-1 activated the pro-apoptotic c-Jun N-terminal kinase (JNK) signal transduction pathway. COBRA and SPIKET compounds represent two new classes of tubulin targeting agents that show promise as anticancer drugs.
Drug Discovery Program and Parker Hughes Cancer Center, Parker Hughes Institute, St Paul, MN 55113, USA. Fatih_Uckun@ih.org
F M
FM
Uckun
C
C
Mao
S T
ST
Jan
H
H
Huang
A O
AO
Vassilev
E A
EA
Sudbeck
C S
CS
Navara
R K
RK
Narla
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use; D005663:Furans / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D011714:Pyrans / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use; D013141:Spiro Compounds / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use
D000970:Antineoplastic Agents; C414943:COBRA 1; D005663:Furans; D011714:Pyrans; C409002:SPIKET-P; D013141:Spiro Compounds